Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 3/20 | 0.33 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047938 | 0.88 | ACHE (0.44) | GAAACHEHSD11B1 | |
| SCHEMBL4583143 | 0.81 | FAAH (0.35) | KDM4EALDH1A1LMNAMAPTCTSD | |
| SCHEMBL4583499 | 0.81 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL4583324 | 0.80 | CTSD (0.34) | CTSDBACE1BACE2HSD11B1 | |
| SCHEMBL4583075 | 0.78 | ALDH1A1 (0.34) | KDM4EALDH1A1GAAMAPTCTSD | |
| SCHEMBL4584697 | 0.77 | — | — | |
| SCHEMBL791198 | 0.77 | ALDH1A1 (0.39) | ALDH1A1LMNAGAACTSDBACE1 | |
| SCHEMBL4585737 | 0.76 | ALDH1A1 (0.42) | KDM4EALDH1A1LMNAGAAMAPT | |
| SCHEMBL4584254 | 0.76 | — | — | |
| SCHEMBL4582805 | 0.75 | CTSD (0.31) | CTSDBACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423180-B2 | Bis(3-amino-4-hydroxyphenyl)adamantane derivatives and process for production thereof | IDEMITSU KOSAN CO., LTD. (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060161016-A1 | Bis(3-amino-4-hydroxyphenyl)adamantane derivatives and process for production thereof | IDEMITSU KOSAN CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1602641-A1 | BIS(3-AMINO-4-HYDROXYPHENYL)ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF | IDEMITSU KOSAN COMPANY LIMITED (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060161016-A1 | Bis(3-amino-4-hydroxyphenyl)adamantane derivatives and process for production thereof | HTR3D, ALKBH3, ALKBH5 | KDM4E 210/4885ALDH1A1 768/4885LMNA 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.